Arctic Bioscience has secured new long-term financing through a bank loan of NOK 15 million. Together with previously disclosed increase in credit facility of NOK 8 million from December 2025, the company has increased available liquidity by a total of NOK 23 million.
The new loan and the increased credit facility are secured through a growth guarantee from Innovation Norway of NOK 6 million and through guarantees from various shareholders of a total of NOK 18 million.
Regarding guarantees from shareholders:
Agreements have been entered into with shareholders who have provided guarantees for the new financing. There will be no guarantee fee to be paid. The guarantors shall, for the entire term of the loan agreement, have an irrevocable right to redeem the entire outstanding amount of the loan on behalf of the company by paying such amount directly to the bank, and to have the resulting claim against the company converted into shares in the company. The claim is convertible by the guarantors at any time into freely tradable shares. Conversion price per share is the lower of 70% x previous 5 trading days VWAP (T+1) from the date the conversion notice is sent, or maximum conversion price of the lower of NOK 3 or 70% x price-per-share in any equity financing in the period where the guarantee is valid.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.